A partial agonist of the NMDA receptor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

GLYX 13

Item No. 21385

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-threonyl-L-prolyl-L-prolyl-L-threoninamide
CAS Number
117928-94-6
Synonyms
  • Rapastinel
Molecular Formula
C18H31N5O6
Formula Weight
413.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMSO: 15 mg/mlEthanol: 10 mg/mlPBS (pH 7.2): 5 mg/ml
SMILES
O=C([C@@H](N)[C@H](O)C)N1[C@H](C(N2[C@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)CCC2)=O)CCC1
InChi Code
InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
InChi Key
GIBQQARAXHVEGD-BSOLPCOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $134

    Add

    5 mg

    $469

    Add
    Product Description

    GLYX 13 is a monoclonal antibody-derived tetrapeptide that acts as a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor.1,2 It is active in vivo when administered intravenously, and it readily passes through the blood-brain barrier.1,3 GLYX 13 has diverse effects in animals, as it blocks neuropathic pain, enhances learning and memory, and significantly reduces anxiety.2,3,4 GLYX 13 induces rapid antidepressant-like effects in animal models and rescued normal behavior in a rat model of autism.5,6,7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Moskal, J.R., Kuo, A.G., Weiss, C., et al. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 49(7), 1077-1087 (2005).

    2. Wood, P.L., Mahmood, S.A., and Moskal, J.R. Antinociceptive action of GLYX-13: An N-methyl-D-aspartate receptor glycine site partial agonist. Neuroport. 19(10), 1059-1061 (2008).

    3. Burgdorf, J., Zhang, X.-l., Weiss, C., et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol. Aging 32(4), 698-706 (2011).

    4. Jin, Z.-L., Liu, J.-X., Liu, X., et al. Anxiolytic effects of GLYX-13 in animal models of posttraumatic stress disorder-like behavior. J. Psychopharmacol. 30(9), 913-921 (2016).

    5. Burgdorf, J., Zhang, X.-l., Nicholson, K.L., et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38(5), 729-742 (2013).

    6. Santini, A.C., Pierantoni, G.M., Gerlini, R., et al. Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders. Biomed. Res. Int. 2014, 234295 (2014).

    7. Yang, B., Zhang, J.-c., Han, M., et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology 233(19-20), 3647-3657 (2016).